Conclusions on the management of heart failure

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 5, Issue SUPPL. 1, 2004, Pages

  Swedberg, Karl ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ACE inhibitors; Aldosterone; ARBs; Guidelines; Heart failure; Myocardial infarction; RAAS; blockers

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; METOPROLOL TARTRATE; PLACEBO; RENIN; VALSARTAN;

ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; COUGHING; DIABETES MELLITUS; DRUG EFFICACY; EUROPE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; MEDICAL SOCIETY; META ANALYSIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 6444230596     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2004.023     Document Type: Article

References (19)

1. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22 1527-60.
2. Lloyd-Jones DM, Larson MG, Beiser A et al. Lifetime risk of developing congestive heart failure. Circulation 1999; 100:1-36.
3. Tsutsumi Y, Matsubara H, Ohkubo N et al. Angiotensin type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res 1998;83:1035-46.
4. Sadoshima J, Izumo S. Molecular characterisation of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circ Res 1993;73:413-23.
5. Sukenaga Y, Kamoshita K, Takai S, Migazaki M. Development of the chymase inhibitor as an anti-tissue remodelling drug in myocardial infarction and some other possibilities. Jpn J Pharmacol 2002; 90 218-22.
6. Farquharson CAJ, Struthers AD. Spironolactone increases nitric oxide bioavailability, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594.
7. Witherow FN, Helmy A, Webb DJ, Fox KAA, Newby DE. Bradykinin contributes to the vasodilatory effects of chronic ACE inhibition in patients with heart failure. Circulation 2001;104:2177-81.
8. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6.
9. Coletta AP, Cleland JG, Freemantle N, Loh H, Memon A, Clark AL. Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM. Eur J Heart Fail 2003;5 697-704.
10. Dickstein K, Kjekshus J. Effect of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360:752-60.
11. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349 1893-906.
12. Cohn JN, Tognoni G.A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
13. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362: 767-71.
14. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003;362:777-81.
15. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362: 759-66.
16. Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
17. Janosi A, Ghali K, Herlitz J et al. Metoprolol CR/XL in post-myocardial infarction patients with chronic heart failure: experience from MERIT-HF. Am Heart J 2003;146:721-8.
18. Simon T, Mary-Krause M, Funck-Brentano C, Lechat J, Jaillon P. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J 2003;24:552-9.
19. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348 1309-21.